Israel - English - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 25 mg - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 5 mg - lenalidomide - multiple myeloma (mm) revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 5 mg - lenalidomide - multiple myeloma (mm) revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

neopharm scientific ltd - a/brisbane/02/2018(h1n1)pdm09-like virus; a/kansas/14/2017 (h3n2) like virus; b/colorado/06/2017- like virus (b/victoria/2/87 lineage); b/phuket/3073/2013 (b/yamagata lineage)-like virus - suspension for injection - b/phuket/3073/2013 (b/yamagata lineage)-like virus 15 mcg / 0.5 ml; b/colorado/06/2017- like virus (b/victoria/2/87 lineage) 15 mcg / 0.5 ml; a/kansas/14/2017 (h3n2) like virus 15 mcg / 0.5 ml; a/brisbane/02/2018(h1n1)pdm09-like virus 15 mcg / 0.5 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - prophylaxis of influenza.

Israel - English - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 20 mg - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

neopharm scientific ltd - cannabidiol drug substance ( cbd bds ); delta-9-tetrahydrocannabinol drug substance ( thc bds ) - oromucosal spray - cannabidiol drug substance ( cbd bds ) 25 mg / 1 ml; delta-9-tetrahydrocannabinol drug substance ( thc bds ) 27 mg / 1 ml - nabiximols - sativex is indicated, as add-on treatment, for symptom relief in patients with moderate to severe spasticity due to multiple sclerosis (ms) who have not responded adequately to other medication and who demonstrate at least 20 % improvement in spasticity related symptoms during a four week trial of therapy.

Israel - English - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 1 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide

Israel - English - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 2 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide

Israel - English - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 3 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.

Israel - English - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 4 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.